Alpha-1 Europe Alliance brings Alpha-1 priorities to the heart of EU policymaking
At the European Parliament, the Alpha-1 Foundation joined experts, patient representatives, and EU policymakers in a session hosted by MEP Olivier Chastel to advance fairer Alpha-1 diagnosis and care.
Alpha-1 Europe Alliance engages in the first European Respiratory Patient Academy in Prague
The Alpha-1 Europe Alliance participated in the inaugural European Respiratory Patient Academy in Prague, joining advocates from across Europe to strengthen patient leadership in respiratory health. Over four days, participants built practical skills, shared experiences, and explored ways to drive meaningful change in research, policy and care.
Two years of impact: Our President reflects on Alpha-1 Europe Alliance’s journey
As the Alpha-1 Europe Alliance (A1EA) celebrates its second anniversary, we spoke with Fernanda, one of the driving forces behind the organization, to reflect on its achievements, the strength of its community, and the road ahead.
DNA & RNA: Understanding the blueprint behind AATD
On October 22-23, 2025, the Alpha-1 Europe Alliance hosted a highly engaging webinar series titled “DNA & RNA: Understanding the Blueprint Behind AATD”, describing in plain language the molecular mechanisms underlying Alpha-1 Antitrypsin Deficiency (AATD).
Alpha-1 Europe Alliance launches first European campaign for International Plasma Awareness Week 2025
From October 6–10, 2025, Alpha-1 Europe Alliance is proud to join the global community in celebrating International Plasma Awareness Week (IPAW2025). This annual initiative raises awareness about the vital importance of plasma donation, honors the generosity of donors, and highlights the life-saving impact of plasma-derived medicinal products (PDMPs) for people living with rare, chronic, and life-threatening conditions.
Alpha-1 Europe Alliance holds its 3rd Annual General Assembly
The Alpha-1 Europe Alliance successfully held its 3rd Annual General Assembly, bringing together member organisations, Board members, and team collaborators. The online gathering held on June 17th served as a moment to reflect on the accomplishments of 2024, and to collectively shape the vision and strategic direction for 2025.
Alpha-1 Europe Alliance present at EMM 2025
The Alpha-1 Europe Alliance proudly participated in the EURORDIS Membership Meeting (EMM) 2025, held in Riga, Latvia, from 22–24 May, with over 140 participants. Representing the Alliance were Frank Willersinn, MD, Board Member of A1EA, and Karin Schmid, President of Alpha-1 Switzerland, a member organisation of the Alliance.
Alpha-1 Europe Alliance participates in IPPC 2025
Fernanda Aspilche, President, and Heinz Stutzenberger, Vice-President of the Alpha-1 Europe Alliance, attended the International Plasma Protein Congress (IPPC 2025), held in Warsaw, Poland, from 20–21 May. This leading annual meeting of the plasma sector brought together 300 participants, including industry leaders, policymakers, healthcare professionals, patient advocates from around the world — and even a plasma donor.
Alpha-1 Europe Alliance joins call to protect patient involvement in EMA decisions
EURORDIS-Rare Diseases Europe and the European Patients’ Forum (EPF) are calling in this joint position statement on EU Member States to protect meaningful patient involvement in the European Medicines Agency (EMA), warning that ongoing negotiations on the revision of EU pharmaceutical legislation risk undermining decades of progress in patient-centred regulation.
Launching the 2025 European Alpha-1 Awareness Day Campaign: The Viking Legacy
Alpha-1 Antitrypsin Deficiency (AATD) is a silent, underrecognised genetic condition that progressively damages the liver, lungs and/or skin. Despite its serious impact, it remains widely undiagnosed across Europe.